

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

RELEASE BY SECURED PARTY

CONVEYING PARTY DATA

Name	Execution Date
Merrill Lynch Business Financial Services, Inc.	10/31/2008

RECEIVING PARTY DATA

Name:	Cytokine Pharmasciences, Inc.
Street Address:	150 South Warner Road, Suite 420
City:	King of Prussia
State/Country:	PENNSYLVANIA
Postal Code:	19406

PROPERTY NUMBERS Total: 35

Property Type	Number
Patent Number:	4932188
Patent Number:	5079009
Patent Number:	5269321
Patent Number:	5490085
Patent Number:	5574040
Patent Number:	5599984
Patent Number:	5620983
Patent Number:	5654186
Patent Number:	5703086
Patent Number:	5719301
Patent Number:	5733932
Patent Number:	5750573
Patent Number:	5753684
Patent Number:	5804446
Patent Number:	5808058

PATENT

500719442

REEL: 021912 FRAME: 0458

OP \$1400.00 4932188

Patent Number:	5808068
Patent Number:	5840305
Patent Number:	5840893
Patent Number:	5846796
Patent Number:	5849793
Patent Number:	5849794
Patent Number:	5854289
Patent Number:	5859062
Patent Number:	5975225
Patent Number:	6008255
Patent Number:	6030615
Patent Number:	6080407
Patent Number:	6143728
Patent Number:	6180676
Patent Number:	6248787
Patent Number:	6297253
Patent Number:	6319894
Patent Number:	6420188
Patent Number:	6645493
Patent Number:	6774227

CORRESPONDENCE DATA

Fax Number: (336)607-7500

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 336/607-7300

Email: lsmith@kilpatrickstockton.com

Correspondent Name: Jason Link - Kilpatrick Stockton LLP

Address Line 1: 1001 West Fourth Street

Address Line 4: Winston-Salem, NORTH CAROLINA 27101

ATTORNEY DOCKET NUMBER:	39298/351985
NAME OF SUBMITTER:	Laura J. Smith

Total Attachments: 4

source=TerminationandReleaseCytokine#page1.tif

source=TerminationandReleaseCytokine#page2.tif

source=TerminationandReleaseCytokine#page3.tif

source=TerminationandReleaseCytokine#page4.tif

**TERMINATION AND RELEASE OF SECURITY INTEREST
IN INTELLECTUAL PROPERTY**


Reference is hereby made to the security interest recorded with the United States Patent and Trademark Office on August 4, 1999, in Reel/Frame 010164/0083 (as amended and supplemented from time to time prior to the date hereof, the "**IP Security Agreement**"), executed by **CYTOKINE PHARMASCIENCES, INC.** ("**Grantor**") in favor of **MERRILL LYNCH BUSINESS FINANCIAL SERVICES INC.**, a Delaware corporation ("**Secured Party**"), pursuant to which Grantor assigned, granted, conveyed, pledged, hypothecated and transferred to Secured Party a security interest in and to all of Grantor's right, title and interest in and to its respective patents, patent applications, and/or patent licenses including, without limitation, those set forth on Schedule 1 attached hereto and those identified in the IP Security Agreement, and all products and proceeds of the foregoing, as more fully described in the IP Security Agreement (collectively, the "**IP Collateral**"); and

WHEREAS, Secured Party wishes to release its security interest in the IP Collateral and retransfer and reassign to Grantor, without representation or warranty, and without recourse, all of Secured Party's right, title and interest in and to the IP Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, Secured Party hereby releases any security interest it may have in the IP Collateral and retransfers and reassigns to Grantor, without representation or warranty, and without recourse, all of Secured Party's right, title and interest in and to the IP Collateral.

IN WITNESS WHEREOF, Secured Party has executed this Termination and Release of Security Interest in Intellectual Property as of this 31 day of October, 2008.

MERRILL LYNCH BUSINESS FINANCIAL SERVICES INC.,
a Delaware corporation

By: 
Name: THOMAS N. AHTO
Title: Duly Authorized Signatory DIRECTOR

ACKNOWLEDGMENT

STATE OF Illinois)

COUNTY OF Cook)

On this 31 day of October, 2008, before me personally appeared THOMAS AHO proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of Merrill Lynch Business Financial Services Inc., who being by me duly sworn did depose and say that he is an authorized officer of said corporation, that the said instrument was signed on behalf of said corporation as authorized by its Board of Directors and that he acknowledged said instrument to be the free act and deed of said corporation.

Patricia Faye Brass
Notary Public
My Commission Expires: 2/21/2012

(NOTARIAL SEAL)



SCHEDULE 1

U.S. Patent No.	Title	Issue Date
4,932,188	Apparatus for closing envelopes	June 12, 1990
5,079,009	Controlled release compositions including polyethylene oxide with urethane cross-linking	January 7, 1992
5,269,321	Retrievable pessary	December 14, 1993
5,490,085	Method for optimizing control of a production unit	February 6, 1996
5,574,040	Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions	November 12, 1996
5,599,984	Guanylhyazones and their use to treat inflammatory conditions	February 4, 1997
5,620,983	Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions	April 15, 1997
5,654,186	Blood-borne mesenchymal cells	August 5, 1997
5,703,086	Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions	December 30, 1997
5,719,301	Method of conjugating double bonds in drying oils	February 17, 1998
5,733,932	Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions	March 31, 1998
5,750,573	Guanylhyazones and their use to treat inflammatory conditions	May 12, 1998
5,753,684	Guanylhyazones and their use to treat inflammatory conditions	May 19, 1998
5,804,446	Blood-borne mesenchymal cells	September 8, 1998
5,808,058	Process for the preparation of 10-OXO-10, 11-dihydro-5H-dibenz (b,f) azepin-5-carboxamide	September 15, 1998
5,808,068	HIV nuclear localization inhibitors	September 15, 1998
5,840,305	Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity	November 24, 1998
5,840,893	Compounds for treating infectious diseases	November 24, 1998
5,846,796	Blood-borne mesenchymal cells	December 8, 1998
5,849,793	HIV matrix protein tyrosine position 29 pocket binders	December 15, 1998
5,849,794	Guanylhyazones and their use to treat inflammatory conditions	December 15, 1998

5,854,289	Guanylhyazones and their use to treat inflammatory conditions	December 29, 1998
5,859,062	Guanylhyazones and their use to treat inflammatory conditions	January 12, 1999
5,975,225	Transportation vehicles with stability enhancement using CG modification	November 2, 1999
6,008,255	Guanylhyazones and their use to treat inflammatory conditions	December 28, 1999
6,030,615	Combination method for treating diseases caused by cytokine-mediated toxicity	February 29, 2000
6,080,407	Diagnostic assays for MIF	June 27, 2000
6,143,728	Guanylhyazones useful for treating diseases associated with T cell activation	November 7, 2000
6,180,676	Guanylhyazones and their use to treat inflammatory conditions	January 30, 2001
6,248,787	Guanylhyazones and their use to treat inflammatory conditions	June 19, 2001
6,297,253	Compounds and methods of use to treat infectious diseases	October 2, 2001
6,319,894	Complexes and combinations of fetuin with therapeutic agents	November 20, 2001
6,420,188	Screening assay for the identification of inhibitors for macrophage migration inhibitory factor	July 16, 2002
6,645,493	Composition containing anti-MIF antibody	November 11, 2003
6,774,227	Therapeutic uses of factors which inhibit or neutralize MIF activity	August 10, 2004